167 related articles for article (PubMed ID: 10618531)
1. Cytokine mRNAs in the nasal-associated lymphoid tissue during influenza virus infection and nasal vaccination.
Matsuo K; Iwasaki T; Asanuma H; Yoshikawa T; Chen Z; Tsujimoto H; Kurata T; Tamura SS
Vaccine; 2000 Jan; 18(14):1344-50. PubMed ID: 10618531
[TBL] [Abstract][Full Text] [Related]
2. Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin).
Matsuo K; Yoshikawa T; Asanuma H; Iwasaki T; Hagiwara Y; Chen Z; Kadowaki SE; Tsujimoto H; Kurata T; Tamura SI
Vaccine; 2000 Jun; 18(24):2713-22. PubMed ID: 10781859
[TBL] [Abstract][Full Text] [Related]
3. Immune responses and protection in different strains of aged mice immunized intranasally with an adjuvant-combined influenza vaccine.
Asanuma H; Hirokawa K; Uchiyama M; Suzuki Y; Aizawa C; Kurata T; Sata T; Tamura S
Vaccine; 2001 Jul; 19(28-29):3981-9. PubMed ID: 11427274
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin A-deficient mice exhibit altered T helper 1-type immune responses but retain mucosal immunity to influenza virus.
Zhang Y; Pacheco S; Acuna CL; Switzer KC; Wang Y; Gilmore X; Harriman GR; Mbawuike IN
Immunology; 2002 Mar; 105(3):286-94. PubMed ID: 11918690
[TBL] [Abstract][Full Text] [Related]
5. Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice.
Trondsen M; Aqrawi LA; Zhou F; Pedersen G; Trieu MC; Zhou P; Cox RJ
Scand J Immunol; 2015 May; 81(5):305-17. PubMed ID: 25737202
[TBL] [Abstract][Full Text] [Related]
6. Induction of antibody-secreting cells and T-helper and memory cells in murine nasal lymphoid tissue.
Wu HY; Nikolova EB; Beagley KW; Russell MW
Immunology; 1996 Aug; 88(4):493-500. PubMed ID: 8881748
[TBL] [Abstract][Full Text] [Related]
7. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
[TBL] [Abstract][Full Text] [Related]
8. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues.
Xu-Amano J; Kiyono H; Jackson RJ; Staats HF; Fujihashi K; Burrows PD; Elson CO; Pillai S; McGhee JR
J Exp Med; 1993 Oct; 178(4):1309-20. PubMed ID: 8376936
[TBL] [Abstract][Full Text] [Related]
9. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin.
Marinaro M; Boyaka PN; Jackson RJ; Finkelman FD; Kiyono H; Jirillo E; McGhee JR
J Immunol; 1999 Jan; 162(1):114-21. PubMed ID: 9886376
[TBL] [Abstract][Full Text] [Related]
10. Oral vaccination with influenza hemagglutinin combined with human pulmonary surfactant-mimicking synthetic adjuvant SF-10 induces efficient local and systemic immunity compared with nasal and subcutaneous vaccination and provides protective immunity in mice.
Kimoto T; Kim H; Sakai S; Takahashi E; Kido H
Vaccine; 2019 Jan; 37(4):612-622. PubMed ID: 30553569
[TBL] [Abstract][Full Text] [Related]
11. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.
Ichinohe T; Watanabe I; Ito S; Fujii H; Moriyama M; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H
J Virol; 2005 Mar; 79(5):2910-9. PubMed ID: 15709010
[TBL] [Abstract][Full Text] [Related]
12. Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccines combined with cholera toxin B subunit.
Tamura S; Kurata H; Funato H; Nagamine T; Aizawa C; Kurata T
Vaccine; 1989 Aug; 7(4):314-20. PubMed ID: 2815967
[TBL] [Abstract][Full Text] [Related]
13. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.
Tamura S; Yamanaka A; Shimohara M; Tomita T; Komase K; Tsuda Y; Suzuki Y; Nagamine T; Kawahara K; Danbara H
Vaccine; 1994 Apr; 12(5):419-26. PubMed ID: 8023550
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of mouse antibody and lymphocyte responses during intranasal vaccination with a lipooligosaccharide-based conjugate vaccine.
Hirano T; Jiao X; Chen Z; Van Waes C; Gu XX
Immunol Lett; 2006 Nov; 107(2):131-9. PubMed ID: 17030407
[TBL] [Abstract][Full Text] [Related]
15. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines.
Asahi Y; Yoshikawa T; Watanabe I; Iwasaki T; Hasegawa H; Sato Y; Shimada S; Nanno M; Matsuoka Y; Ohwaki M; Iwakura Y; Suzuki Y; Aizawa C; Sata T; Kurata T; Tamura S
J Immunol; 2002 Mar; 168(6):2930-8. PubMed ID: 11884464
[TBL] [Abstract][Full Text] [Related]
16. IgA antibody-forming cell responses in the nasal-associated lymphoid tissue of mice vaccinated by intranasal, intravenous and/or subcutaneous administration.
Asanuma H; Aizawa C; Kurata T; Tamura S
Vaccine; 1998 Aug; 16(13):1257-62. PubMed ID: 9682388
[TBL] [Abstract][Full Text] [Related]
17. Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue.
Hagiwara Y; McGhee JR; Fujihashi K; Kobayashi R; Yoshino N; Kataoka K; Etani Y; Kweon MN; Tamura S; Kurata T; Takeda Y; Kiyono H; Fujihashi K
J Immunol; 2003 Feb; 170(4):1754-62. PubMed ID: 12574339
[TBL] [Abstract][Full Text] [Related]
18. The pulmonary environment promotes Th2 cell responses after nasal-pulmonary immunization with antigen alone, but Th1 responses are induced during instances of intense immune stimulation.
Jones HP; Hodge LM; Fujihashi K; Kiyono H; McGhee JR; Simecka JW
J Immunol; 2001 Oct; 167(8):4518-26. PubMed ID: 11591779
[TBL] [Abstract][Full Text] [Related]
19. Cross-protection against influenza B type virus infection by intranasal inoculation of the HA vaccines combined with cholera toxin B subunit.
Kikuta K; Hirabayashi Y; Nagamine T; Aizawa C; Ueno Y; Oya A; Kurata T; Tamura S
Vaccine; 1990 Dec; 8(6):595-9. PubMed ID: 1965078
[TBL] [Abstract][Full Text] [Related]
20. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.
Asahi-Ozaki Y; Itamura S; Ichinohe T; Strong P; Tamura S; Takahashi H; Sawa H; Moriyama M; Tashiro M; Sata T; Kurata T; Hasegawa H
Microbes Infect; 2006 Oct; 8(12-13):2706-14. PubMed ID: 16968669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
